I'm hoping that cooler heads prevail - that this is just part of the strategy here - and that they are hoping that the results from the Covid trials put them into a much stronger bargaining position. Haven't forgotten Dutch's comment re Pfizer!

All of their library (molecules) needs way more attention - how many more years will this be stalled if we go Plan B and C?

Hope Ori, who cashed in on a 2016 position in thir portfolio, decides to get Hepalink and Dart onboard for more of a guiding hand from BP too.